Effect of pressure reducing effect of Ripasudil eye drops in patients with high pressure within the eye
- Conditions
- Health Condition 1: H401- Open-angle glaucoma
- Registration Number
- CTRI/2022/09/045191
- Lead Sponsor
- Sankara eye hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients with Central Corneal Thickness corrected intraocular pressure more than or equal to 22mmHg which includes primary open angle glaucoma and ocular hypertension
Patients with history of ocular trauma
Patients with history of intraocular surgery
Secondary glaucomas like angle closure glaucoma, neovascular glaucoma, pseudo-exfoliative glaucoma, pigmentary glaucoma
Patients with pre-existing corneal diseases
Pre-existing dry eye
Patients with allergic conjunctivitis
Pregnant and lactating women
Patients who are not willing for follow up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the intraocular pressure lowering effect of 0.4% Ripasudil eye drops in patients with primary open angle glaucoma and ocular hypertensionTimepoint: Intraocular pressure is measured at baseline, 4 weeks, 12 weeks and 24 weeks
- Secondary Outcome Measures
Name Time Method To assess the incidence of side effects with RipasudilTimepoint: By assessing the side effects at 1st month, 3rd month and 6th month;To assess the IOP lowering effect of Ripasudil as a monotherapy or as an additive agentTimepoint: By comparing IOP at presentation (baseline) and at 1st month, 3rd months, 6th months;To assess the requirement of additional lubricants to continue RipasudilTimepoint: By assessing the side effects at 1st month, 3rd month and 6th month;To assess the requirement of additional ocular hypotensive drug in those patients on Ripasudil therapyTimepoint: By comparing IOP at presentation (baseline) and at 1st month, 3rd months, 6th months